221 related articles for article (PubMed ID: 16481875)
1. Managing diabetic nephropathy: recent studies.
Lit YZ; Meyer T
Curr Opin Nephrol Hypertens; 2006 Mar; 15(2):111-6. PubMed ID: 16481875
[TBL] [Abstract][Full Text] [Related]
2. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
3. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
Azadpour M; Lamas GA
Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
[TBL] [Abstract][Full Text] [Related]
4. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
[TBL] [Abstract][Full Text] [Related]
5. Dual blockade of the renin-angiotensin system in diabetic nephropathy.
Wade VL; Gleason BL
Ann Pharmacother; 2004; 38(7-8):1278-82. PubMed ID: 15187210
[TBL] [Abstract][Full Text] [Related]
6. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
[TBL] [Abstract][Full Text] [Related]
7. Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease.
Song JH; Cha SH; Hong SB; Kim DH
J Hypertens Suppl; 2006 Mar; 24(1):S101-6. PubMed ID: 16601562
[TBL] [Abstract][Full Text] [Related]
8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
9. Approach to the treatment of diabetic nephropathy.
Burke JM
Pharm Pract Manag Q; 1997 Jul; 17(2):26-35. PubMed ID: 10168175
[TBL] [Abstract][Full Text] [Related]
10. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
Jacobsen P; Rossing K; Parving HH
Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
[TBL] [Abstract][Full Text] [Related]
11. [Role of the renin-angiotensin system in the pathogenesis, clinical picture and treatment of diabetic nephropathy].
Wittmann I; Degrell P; Komáromy A; Molnár GA; Wagner Z; Wagner L; Mazák I; Nagy J
Orv Hetil; 2003 Mar; 144(13):613-9. PubMed ID: 12728786
[TBL] [Abstract][Full Text] [Related]
12. Early detection of endothelial dysfunction and early therapeutic correction effectively restore renal function in type 2 diabetic nephropathy.
Futrakul N; Butthep P
Ren Fail; 2005; 27(4):493-4. PubMed ID: 16060141
[No Abstract] [Full Text] [Related]
13. Emerging therapeutic strategies in diabetic nephropathy.
Ravera M; Re M; Weiss U; Deferrari L; Deferrari G
J Nephrol; 2007; 20 Suppl 12():S23-32. PubMed ID: 18050139
[TBL] [Abstract][Full Text] [Related]
14. Improving microvascular outcomes in patients with diabetes through management of hypertension.
McGill JB
Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
[TBL] [Abstract][Full Text] [Related]
15. Diabetic nephropathy: common questions.
Thorp ML
Am Fam Physician; 2005 Jul; 72(1):96-9. PubMed ID: 16035688
[TBL] [Abstract][Full Text] [Related]
16. [Multilevel blockade of the renin-angiotensin-aldosterone system in the treatment of diabetic nephropathy].
Fronczyk A; Majkowska L
Przegl Lek; 2007; 64(2):81-5. PubMed ID: 17892038
[TBL] [Abstract][Full Text] [Related]
17. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Weber MA
Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
Tocci G; Sciarretta S; Facciolo C; Volpe M
Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):767-76. PubMed ID: 17605654
[TBL] [Abstract][Full Text] [Related]
19. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
Kuti EL; Baker WL; White CM
Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720
[TBL] [Abstract][Full Text] [Related]
20. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease.
Ripley E
Am Heart J; 2009 Jun; 157(6 Suppl):S7-S16. PubMed ID: 19450722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
